A. Young, United Kingdom

Institute of Psychiatry, Psychology & Neuroscience, King's College London Psychological Medicine, Centre for Affective Disorders
Allan Young is the Chair of Mood Disorders and is Director of the Centre for Affective Disorders in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London, UK (where he is also interim Vice-Dean for Academic Psychiatry). Professor Young is the cluster and theme lead in the Translational Therapeutics Cluster at the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre. He is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust, where he is also a consultant psychiatrist and the head of the National Affective Disorders Service. Professor Young is a member of several editorial boards and professional and scientific societies. He is immediate Past-President of the International Society for Affective Disorders, President of the British Association of Psychopharmacology and the immediate Past-Chair of the Special Committee for Psychopharmacology of the Royal College of Psychiatrists. He is also a trustee of the patient and family charity, Bipolar UK, and an independent academic unit, The Drug Safety Research Unit. Professor Young’s research interests focus on the causes of, and treatments for, severe psychiatric illnesses, particularly mood disorders. He has published more than 500 peer-reviewed publications and several books about psychopharmacology and affective disorders.

Moderator of 1 Session

Industry Session
Date
Mon, 12.04.2021
Session Time
13:30 - 14:15
Room
Industry 1
Session Description
Treatment-Resistant Depression - SUPPORTED BY Janssen

Session Icon
Product Theatre

Presenter of 8 Presentations

Product Theatre not Included in the Main Event CME / CPD Credit (ID 1151) No Topic Needed

Welcome and introduction

Session Icon
Product Theatre
Date
Mon, 12.04.2021
Session Time
13:30 - 14:15
Room
Industry 1
Lecture Time
13:30 - 13:33
Product Theatre not Included in the Main Event CME / CPD Credit (ID 1151) No Topic Needed

Unmet needs in major depressive disorder (MDD) and introduction to SPRAVATO®

Session Icon
Product Theatre
Date
Mon, 12.04.2021
Session Time
13:30 - 14:15
Room
Industry 1
Lecture Time
13:33 - 13:41
LIVE - Best of 2020 : Research that Advanced Psychiatry and Changed our Practice (ID 778) No Topic Needed

Live Q&A

Session Icon
Live
Date
Mon, 12.04.2021
Session Time
15:30 - 17:00
Room
Channel 2
Lecture Time
16:39 - 16:59
Product Theatre not Included in the Main Event CME / CPD Credit (ID 1151) No Topic Needed

Moderated panel Q&A discussion

Session Icon
Product Theatre
Date
Mon, 12.04.2021
Session Time
13:30 - 14:15
Room
Industry 1
Lecture Time
13:55 - 14:15
Industry Session not Included in the Main Event CME / CPD Credit (ID 1125) No Topic Needed

The unmet need in MDD: importance of rapid treatment and effective emergency care

Session Icon
Pre-Recorded with Live Q&A
Date
Sat, 10.04.2021
Session Time
19:00 - 20:30
Room
Industry 1
Lecture Time
19:05 - 19:25
Sunday, 11 April: Highlights of the Day (ID 1170) No Topic Needed

Highlights of the Day

Session Icon
Live TV
Date
Sun, 11.04.2021
Session Time
17:00 - 17:30
Room
EPA TV
Lecture Time
17:00 - 17:30
Industry Session not Included in the Main Event CME / CPD Credit (ID 1125) No Topic Needed

LIVE Q&A: Panel discussion and audience Q&A

Session Icon
Pre-Recorded with Live Q&A
Date
Sat, 10.04.2021
Session Time
19:00 - 20:30
Room
Industry 1
Lecture Time
20:05 - 20:25
LIVE - Best of 2020 : Research that Advanced Psychiatry and Changed our Practice (ID 778) No Topic Needed

BOEPA003 - Bipolar Affective Disorder

Session Icon
Live
Date
Mon, 12.04.2021
Session Time
15:30 - 17:00
Room
Channel 2
Lecture Time
16:16 - 16:39

ABSTRACT

Abstract Body

Abstract: Biomarkers for diagnosis and treatment of Bipolar Disorder: hope or hype?

Professor Allan Young, Centre for Affective Disorders, IoPPN, KCL London, SE5 8AF.

allan.young@kcl.ac.uk

The use of “biomarkers” (biological markers) in basic and clinical research as well as in clinical practice has become so commonplace in many areas of medicine that their presence as primary endpoints in clinical trials is now widely accepted. In clinical disciplines where specific biomarkers have been well characterized and repeatedly shown to correctly predict relevant clinical outcomes across a variety of treatments and populations, this use is entirely justified and appropriate. However, the validity of biomarkers in most psychiatric disorders continues to be evaluated. This lecture will review the current conceptual status of biomarkers as clinical and diagnostic tools for bipolar disorder and as surrogate endpoints in clinical research in bipolar disorder. The conceptual background in terms of current diagnostic categories and research domain criteria will be discussed and the various approaches with putative value (e.g., brain imaging, genetics, and neuroendocrinology) reviewed (1, 2). The lecture will end with a discussion of approaches to evaluating biomarkers of lithium response (3).

epatriangleabstractahy2021.png

References:

Wise et al, Mol Psychiatry. 2016 May 24. doi: 10.1038/mp.2016.72. [Epub ahead of print];

Young AH. Harv Rev Psychiatry. 2014 Nov-Dec;22(6):331-3

Bellivier F, Young AH, et al, Bipolar Disord. 2020 Oct 23. doi: 10.1111/bdi.13023. Online ahead of print.

Hide